The Immune Response Corporation Announces Publication Of Data From a Previous Multiple Sclerosis Vaccine Study

Company's BV6 TCR Peptide Vaccine Induces

An Immune Response in 80% of Vaccinated MS Patients



Apr 30, 2001, 01:00 ET from The Immune Response Corporation

    CARLSBAD, Calif., April 30 /PRNewswire/ -- The Immune Response Corporation
 (Nasdaq:   IMNR) announced the publication of data on their investigational
 T Cell Receptor (TCR) peptide vaccine for multiple sclerosis (MS) showing that
 it induced a specific response (stimulation index >5) in 80% of the patients
 treated.  The objective of the Company's TCR vaccine program is to induce an
 immune response that inactivates the T cells thought to be pathogenic in MS.
 The article appears in the May issue of the Journal of Neuroscience Research.
 Eight of ten patients given five 300 microgram injections of the TCR peptides
 emulsified in Incomplete Freund's adjuvant (IFA) during the 48 week open label
 trial developed specific cell mediated responses as measured by both
 delayed-type hypersensitive (DTH) skin tests and lymphocyte proliferation
 assays (LPA).  No responses against an irrelevant peptide were observed, and
 neurologic assessments, on average, remained stable during the trial.
     "These data, from our Phase I MS trial completed in 1999, suggest that our
 BV6 peptide is highly immunogenic in MS patients, and justify its inclusion as
 part of a combination peptide vaccine in our future MS trials," said Richard
 M. Bartholomew, Ph.D., Executive Director of Research Operations for The
 Immune Response Corporation.  "Based on data from previous clinical trials and
 over 160 pathogenic T cell clones isolated from many different MS patients, we
 believe that if commercially approved our TCR therapeutic vaccine combining
 BV5, BV6 and BV13.1 could potentially be used to treat approximately 90% of
 the patients suffering from MS."
     Currently, the Company has a 60 patient Phase I/II TCR combination peptide
 vaccine study under way.  The trial is being conducted at six centers located
 within the states of Washington and Oregon.  The double blind,
 placebo-controlled trial will monitor safety, immunogenicity and clinical
 benefits.
 
     The Immune Response Corporation is a biopharmaceutical company based in
 Carlsbad, California, developing immune-based therapies to induce specific
 T-cell responses for the treatment of HIV, autoimmune diseases and cancer.  In
 addition, the Company is developing a targeted non-viral delivery technology
 for gene therapy, which is designed to enable the delivery of genes directly
 to the liver via intravenous injection.
 
     NOTE:  News releases are available through PR Newswire Company News
 On-Call fax service.  For a menu of available news releases or to retrieve a
 specific release made by The Immune Response Corporation, please call
 800-758-5804, extension 434675.  Please retain these numbers for future
 reference.  Company information can also be located on the Internet Web Site:
 http://www.imnr.com.
 
     This news release contains forward-looking statements.  Actual results
 could vary materially from those expected due to a variety of risk factors,
 including, but not limited to, whether data generated from previous trials can
 be replicated in future clinical trials, whether clinical trials will be
 successfully concluded and whether an MS vaccine will be approved for
 marketing or be successfully commercialized.  Those factors are discussed more
 thoroughly in The Immune Response Corporation's SEC filings, including but not
 limited to its report on Form 10-K for the year ended December 31, 2000.  The
 Company undertakes no obligation to publicly release the result of any
 revisions to these forward-looking statements, which may be made to reflect
 events or circumstances after the date hereof or to reflect the occurrence of
 unanticipated events.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X62016188
 
 

SOURCE The Immune Response Corporation
    CARLSBAD, Calif., April 30 /PRNewswire/ -- The Immune Response Corporation
 (Nasdaq:   IMNR) announced the publication of data on their investigational
 T Cell Receptor (TCR) peptide vaccine for multiple sclerosis (MS) showing that
 it induced a specific response (stimulation index >5) in 80% of the patients
 treated.  The objective of the Company's TCR vaccine program is to induce an
 immune response that inactivates the T cells thought to be pathogenic in MS.
 The article appears in the May issue of the Journal of Neuroscience Research.
 Eight of ten patients given five 300 microgram injections of the TCR peptides
 emulsified in Incomplete Freund's adjuvant (IFA) during the 48 week open label
 trial developed specific cell mediated responses as measured by both
 delayed-type hypersensitive (DTH) skin tests and lymphocyte proliferation
 assays (LPA).  No responses against an irrelevant peptide were observed, and
 neurologic assessments, on average, remained stable during the trial.
     "These data, from our Phase I MS trial completed in 1999, suggest that our
 BV6 peptide is highly immunogenic in MS patients, and justify its inclusion as
 part of a combination peptide vaccine in our future MS trials," said Richard
 M. Bartholomew, Ph.D., Executive Director of Research Operations for The
 Immune Response Corporation.  "Based on data from previous clinical trials and
 over 160 pathogenic T cell clones isolated from many different MS patients, we
 believe that if commercially approved our TCR therapeutic vaccine combining
 BV5, BV6 and BV13.1 could potentially be used to treat approximately 90% of
 the patients suffering from MS."
     Currently, the Company has a 60 patient Phase I/II TCR combination peptide
 vaccine study under way.  The trial is being conducted at six centers located
 within the states of Washington and Oregon.  The double blind,
 placebo-controlled trial will monitor safety, immunogenicity and clinical
 benefits.
 
     The Immune Response Corporation is a biopharmaceutical company based in
 Carlsbad, California, developing immune-based therapies to induce specific
 T-cell responses for the treatment of HIV, autoimmune diseases and cancer.  In
 addition, the Company is developing a targeted non-viral delivery technology
 for gene therapy, which is designed to enable the delivery of genes directly
 to the liver via intravenous injection.
 
     NOTE:  News releases are available through PR Newswire Company News
 On-Call fax service.  For a menu of available news releases or to retrieve a
 specific release made by The Immune Response Corporation, please call
 800-758-5804, extension 434675.  Please retain these numbers for future
 reference.  Company information can also be located on the Internet Web Site:
 http://www.imnr.com.
 
     This news release contains forward-looking statements.  Actual results
 could vary materially from those expected due to a variety of risk factors,
 including, but not limited to, whether data generated from previous trials can
 be replicated in future clinical trials, whether clinical trials will be
 successfully concluded and whether an MS vaccine will be approved for
 marketing or be successfully commercialized.  Those factors are discussed more
 thoroughly in The Immune Response Corporation's SEC filings, including but not
 limited to its report on Form 10-K for the year ended December 31, 2000.  The
 Company undertakes no obligation to publicly release the result of any
 revisions to these forward-looking statements, which may be made to reflect
 events or circumstances after the date hereof or to reflect the occurrence of
 unanticipated events.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X62016188
 
 SOURCE  The Immune Response Corporation

RELATED LINKS

http://www.imnr.com